Get the Stockscreener App
22.26
26.48%
4.66
Acadia Pharmaceuticals Inc stock is traded at $22.26, with a volume of 17.77M.
It is up +26.48% in the last 24 hours and up +52.78% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$17.60
Open:
$18.37
24h Volume:
17.77M
Relative Volume:
8.92
Market Cap:
$3.73B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
123.67
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+27.64%
1M Performance:
+52.78%
6M Performance:
+32.74%
1Y Performance:
+49.90%
1-Day Range:
$18.37
$25.23
1-Week Range:
$16.86
$25.23
52-Week Range:
$13.40
$25.23
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.26 | 2.92B | 890.53M | 30.57M | 80.53M | 0.18 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer - Yahoo Finance
Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital - Yahoo Finance
Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript - MSN
Healthcare Stocks Lifted By Legal Wins And Drug Approvals - Finimize
Sector Update: Health Care - marketscreener.com
Acadia Pharmaceuticals secures patent protection for Parkinson’s drug - Investing.com Australia
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid - GuruFocus
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid - MSN
Acadia Pharmaceuticals (ACAD) Wins Key Patent Case for Nuplazid | ACAD Stock News - GuruFocus
Acadia (ACAD) Wins Patent Dispute, Secures Future Revenues | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (p - GuruFocus
Acadia confirms court ruling in favor of Nuplazid formulation patent - TipRanks
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case Agai - GuruFocus
Acadia Pharmaceuticals (ACAD) Sees Price Target Increase from Ne - GuruFocus
Acadia Pharma (ACAD) announces that Delaware Court has ruled in its favor for NUPLAZID litigation - StreetInsider
Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation - marketscreener.com
Oppenheimer Raises Price Target for Acadia Pharmaceuticals (ACAD) | ACAD Stock News - GuruFocus
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation - Yahoo Finance
Acadia Wins Patent Ruling Over Aurobindo’s Nuplazid Copies (2) - Bloomberg Law News
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Benzinga
Acadia Pharmaceuticals (ACAD) Soars Following Patent Victory - GuruFocus
Acadia Pharmaceuticals (ACAD) Wins Patent Infringement Case | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals shares surge on patent ruling - Investing.com
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans - Investing.com Australia
Acadia Pharmaceuticals at BofA Conference: Strategic Growth Plans By Investing.com - Investing.com India
Transcript : ACADIA Pharmaceuticals Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
ACADIA Pharmaceuticals: Advancing On Several Fronts (NASDAQ:ACAD) - Seeking Alpha
Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data - MSN
Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders - MSN
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareho - GuruFocus
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - Yahoo Finance
Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
Acadia Pharmaceuticals (ACAD) Prepares for Stock Sale by Shareholders - GuruFocus
Acadia Pharma (ACAD) Files for 43.58M Share Offering by Selling Stockholders - StreetInsider
New Parkinson's Disease Therapies Market Outlook & Research - openPR.com
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth - TipRanks
Schizophrenia Market Growth Projections 2024-2034: - openPR.com
Acadia: Q1 Earnings Snapshot - Norwalk Hour
Cautious Hold Rating on ACADIA Pharmaceuticals Amid Mixed Performance and Future Prospects - TipRanks
Acadia Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
ACADIA Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Acadia Pharmaceuticals Q1 2025 slides: revenue jumps 19%, pipeline timeline accelerated - Investing.com Canada
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):